口服化疗补贴与骨髓瘤医保受益人中使用免疫调节药物之间的关系
该研究利用SEER-Medicare数据,纳入2007至2011年确诊的3038例骨髓瘤Part D受益人,分析低收入补贴(LIS)与免疫调节药物(IMiDs)使用的关系。结果显示LIS受助者首次IMiD处方自付费用中位数为3美元,非受助者为3178美元;LIS与75至84岁患者接受IMiDs概率提高32%相关,并与所有年龄组续药延迟风险降低相关(调整相对风险0.54)。
要点
- LIS受助者首次IMiD处方自付费用中位数为3美元,非受助者为3178美元
- 75至84岁LIS受助者接受IMiDs概率提高32%(95%CI 16%至47%)
- LIS受助者续药延迟风险降低(调整相对风险0.54,95%CI 0.32至0.92)
核心结论
- 未获得LIS的骨髓瘤医保受益人在获取口服抗癌治疗方面面临显著经济障碍,需政策制定者紧急关注。
- 限制IMiDs等昂贵抗癌药物的自付费用可能改善骨髓瘤患者获得口服治疗的机会。
研究设计与样本
- 利用SEER-Medicare数据识别2007至2011年确诊骨髓瘤的Part D受益人,共3038例。
- 采用多变量模型校正社会人口学和临床特征,分析LIS与IMiD为基础治疗使用、IMiD续药延迟及治疗第一年部分健康结局的关系。
主要发现
- 3038例受益人中有41%接受一线IMiDs。
- 首次IMiD处方自付费用中位数:LIS受助者3美元 vs 非受助者3178美元;治疗第一年自付费用中位数:LIS受助者6美元 vs 非受助者5623美元。
- 75至84岁受益人接受LIS与接受IMiDs概率提高32%相关(95%CI 16%至47%)。
- 所有年龄组中LIS受助者续药延迟风险显著降低(调整相对风险0.54,95%CI 0.32至0.92)。
- LIS受助者与非受助者治疗持续时间无显著差异(中位数7.6个月)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The low-income subsidy (LIS) substantially lowers out-of-pocket costs for qualifying Medicare Part D beneficiaries who receive orally administered chemotherapy. We examined the association of LIS with the use of novel oral immunomodulatory drugs (IMiDs; lenalidomide and thalidomide) among beneficiaries with myeloma, who can receive either orally administered or parenteral (bortezomib-based) therapy. Methods Using SEER-Medicare data, we identified Part D beneficiaries diagnosed with myeloma in 2007 to 2011. In multivariable models adjusted for sociodemographic and clinical characteristics, we analyzed associations between the LIS and use of IMiD-based therapy, delays between IMiD refills, and select health outcomes during the first year of therapy. Results Among 3,038 beneficiaries, 41% received first-line IMiDs. Median out-of-pocket cost for the first IMiD prescription was $3,178 for LIS nonrecipients and $3 for LIS recipients, whereas the respective median costs for the first year of therapy were $5,623 and $6, respectively. Receipt of the LIS was associated with a 32% higher (95% CI, 16% to 47%) probability of receiving IMiDs among beneficiaries age 75 to 84 years and a significantly lower risk of delays between refills in all age groups (adjusted relative risk, 0.54; 95% CI, 0.32 to 0.92). Duration of therapy did not significantly differ between LIS recipients and nonrecipients (median, 7.6 months). Patients treated with IMiDs had significantly fewer emergency department visits and hospitalizations compared with patients receiving bortezomib (without IMiDs), but 1-year overall survival and cumulative Medicare costs were similar. Conclusion Medicare beneficiaries with myeloma who do not receive LISs face a substantial financial barrier to accessing orally administered anticancer therapy, warranting urgent attention from policymakers. Limiting out-of-pocket costs for expensive anticancer drugs like the IMiDs may improve access to oral therapy for patients with myeloma.
引用
- Olszewski AJ, Dusetzina SB, Eaton CB, et al. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma. J Clin Oncol. 2017. PMID: 28541791. doi:10.1200/JCO.2017.72.2447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。